STERLINBIO

Paysan Publishers Private Limited has submitted to the Exchange a copy of Disclosure under Regulation 7(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and Regulation 13(4A) of Seurities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 and amendments thereof.

Sterling Biotech Limited has submitted to the Exchange a copy of disclosure under Regulation 7(3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and Regulation 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Sterling Biotech Limited has submitted to the Exchange a copy of the Disclosure under Regulation 8A(4) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers), 1997.

Sterling Biotech Limited has submitted the Exchange a copy of disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 1997.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2011.

Sterling Biotech Limited has submitted the Exchange a copy of disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 1997.

Sterling Biotech Limited has submitted the Exchange a copy of disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 1997.

Sterling Biotech Limited has submitted the Exchange a copy of disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 1997.

Sterling Biotech Limited has submitted the Exchange a copy of disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 1997.

Sterling Biotech Limited has submitted the Exchange a copy of disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 1997.

Sterling Biotech Limited has submitted the Exchange a copy of disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 1997.

Sterling Biotech Limited has submitted to the Exchange a copy of Disclosure pursuant to Regulation 8A(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Sterling Biotech Limited has submitted to the Exchange a copy of Disclosure pursuant to Regulation 8A(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Sterling Biotech Limited has submitted to the Exchange a copy of Disclosure pursuant to Regulation 8A(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Sterling Biotech Limited has submitted to the Exchange a copy of Disclosure pursuant to Regulation 8A(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Sterling Biotech Limited has informed the Exchange that the Annual General Meeting for the financial year ended December 31, 2010 will be held on June 30, 2011. Further the Register of Members and Share Transfer Books of the Company shall remain closed from June 23, 2011 to June 30, 2011 (both days inclusive) for the purpose of payment of Dividend for the financial year ended on December 31, 2010 @ 50% (i.e. Rs.0.50 per equity share of Re.1/- each) recommended by the Board of Directors of the Company at their meeting held on March 31, 2011 subject to confirmation of members at the Annual Gener

Sterling Biotech Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 31, 2011 has recommended 50% (Rs. 0.50 per equity share of F.V. of Re.1/- each) dividend on the equity shares for the financial year ended December 31, 2010 subject to approval of the members at the ensuing Annual General Meeting.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2010.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2011.

Sterling Biotech Limited has submitted to the Exchange a disclosure pursuant to Regulation 8A(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2010.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 42802.91 lacs for quarter ending on 31-DEC-2010 against Rs. 36841.18 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 2294.47 lacs for the quarter ending on 31-DEC-2010 against Rs. 10781.59 lacs for the quarter ending on 31-DEC-2009.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2010.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 40978.47 lacs for quarter ending on 30-SEP-2010 against Rs. 36254.97 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 3063.21 lacs for the quarter ending on 30-SEP-2010 against Rs. 4097.7 lacs for the quarter ending on 30-SEP-2009.

Sterling Biotech Limited has informed the Exchange that the company had issued FCCB of USD 175 million in September 2005. Of these bonds. (1) FCCB with Nominal Value of USD 135.46 million are converted in to Equity Shares adding Rs.593.61 Crs to net worth of Company. (2) FCCB with Nominal Value of USD 39.54 million (equivalent to Rs.208.13 Crs) has been repaid by company as. (a) FCCB with Nominal Value of USD 21.225 million were Bought Back in terms of the Reserve Bank Guidelines for Buy-back of the FCCBs. (b) The Outstanding FCCB with Nominal Value of USD 18.315 million which were due for red

Sterling Biotech Limited has informed the Exchange regarding the Cancellation of Foreign Currency Convertible Bonds ("FCCBs").

Sterling Biotech Limited has informed the Exchange regrding the outcome of Annual GeneraL Meeting held on June 30, 2010.

Sterling Biotech Limited has informed the Exchange that pursuant to Clause 6.3.26 of the Offering Circular dated May 14, 2007, the conversion price of USD 250 Million Zero Coupon Convertible Bonds (FCCB) due 2012 as on May 15, 2010 (Reset Date) has been reset at Rs.163.13 from Rs.204.576 per share.

Sterling Biotech Limited has informed the Exchange that the Annual General Meeting for the financial year ended December 31, 2009 will be held on June 30, 2010. Further the Register of Members and Share Transfer Books of the Company shall remain closed from June 23, 2010 to June 30, 2010 (both days inclusive) for the purpose of payment of Dividend for the financial year ended on December 31, 2009 @ 50% (i.e. Rs.0.50 per equity share of Re.1/- each) recommended by the Board of Directors of the Company at their meeting held on March 31, 2010 subject to confirmation of members at the Annual Gener

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 38278.25 lacs for quarter ending on 31-MAR-2010 against Rs. 34957.49 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 4704.19 lacs for the quarter ending on 31-MAR-2010 against Rs. 4772.8 lacs for the quarter ending on 31-MAR-2009.

Sterling Biotech Limited has informed the Exchange that the Company has received the letter, dated March 19, 2010, from The Calcutta Stock Exchange Ltd. approving the voluntary de-listing of equity shares of the Company.

Sterling Biotech Limited has informed the Exchange that the Board of Directors at their meeting held on March 31, 2010 has recommended 50% (Rs. 0.50 per equity share of F.V of Re. 1/- each) dividend on the equity shares for the financial year ended December 31, 2009 subject to approval of the members at the ensuing Annual General Meeting.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the year ended on 31-DEC-2009 as follows: Net Sales of Rs. 143817.29 lacs for year ending on 31-DEC-2009 against Rs. 117838.07 lacs for the year ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 23699.53 lacs for the year ending on 31-DEC-2009 against Rs. 21918.13 lacs for the year ending on 31-DEC-2008.

Sterling Biotech Limited has informed the Exchange that the company will publish Audited Results for the financial year instead of publishing unaudited quarterly results for the quarter ended on December 31, 2009. The Audited Results will be considered and published within the time limits.

Sterling Biotech Limited has informed the Exchange regarding the Cancellation of Foreign Currency Convertible Bonds (FCCBs). The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/sterlingbio_FCCB_12012010.zip target=NEW> For more details click here.</a>

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 36254.97 lacs for quarter ending on 30-SEP-2009 against Rs. 30166.97 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 4097.7 lacs for the quarter ending on 30-SEP-2009 against Rs. 6124.98 lacs for the quarter ending on 30-SEP-2008.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 35763.65 lacs for quarter ending on 30-JUN-2009 against Rs. 34957.49 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 4047.44 lacs for the quarter ending on 30-JUN-2009 against Rs. 4772.8 lacs for the quarter ending on 31-MAR-2009.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the half year ended on 30-JUN-2009 as follows: Net Sales of Rs. 70721.14 lacs for half year ending on 30-JUN-2009 against Rs. 54597.9 lacs for the half year ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 8820.24 lacs for the half year ending on 30-JUN-2009 against Rs. 11221.79 lacs for the half year ending on 30-JUN-2008.

Sterling Biotech Limited has informed the Exchange that Annual General Meeting of members of the Company was held on June 30, 2009. The members present at the meeting have unanimously passed all the resolutions as per the notice of Annual General Meeting, briefly summarized as under: Ordinary Business and Ordinary Resolution: (1) Adoption of Annual Accounts for the year ended December 31, 2008. (2) Re-appointment of Shri V.D. Joshi as Director of the Company. (3) Re-appointment of Shri P.B. Mehta as Director of the Company (4) Appointment of H.S.Hathi & Co., as Auditors of the Company for the

Sterling Biotech Limited has informed the Exchange that the Annual General Meeting for the financial year ended on December 31, 2008 will be held on June 30, 2009. Further, the Register of Members and Share Transfer Books of the Company shall remain closed from June 23, 2009 to June 30, 2009 (both days inclusive) for the purpose of payment of Dividend for the financial year ended on December 31, 2008 @ 50% per equity share of Re. 1/- each recommended by the Board of Directors of the Company at their meeting held on March 31, 2009 subject to confirmation of members at the Annual General Meeting

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 34957.49 lacs for quarter ending on 31-MAR-2009 against Rs. 33073.2 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 4772.8 lacs for the quarter ending on 31-MAR-2009 against Rs. 4571.36 lacs for the quarter ending on 31-DEC-2008.

Sterling Biotech Limited has informed the Exchange that the Board of Director at its meeting held on March 31, 2009, the Board has recommended 50% (Rs 0.50 per equity share of F.V. of Re. 1 /- each) dividend on the equity shares for the financial year ended December 31, 2008 subject to approval of the members.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 33073.2 lacs for quarter ending on 31-DEC-2008 against Rs. 26129.52 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 4571.36 lacs for the quarter ending on 31-DEC-2008 against Rs. 4931.66 lacs for the quarter ending on 31-DEC-2007.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the year ended on 31-DEC-2008 as follows: Net Sales of Rs. 117838.07 lacs for year ending on 31-DEC-2008 against Rs. 91084.76 lacs for the year ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 21918.13 lacs for the year ending on 31-DEC-2008 against Rs. 18370.53 lacs for the year ending on 31-DEC-2007.

Sterling Biotech Limited has submitted to the Exchange a disclosure pursuant to Regulation 8A(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Sterling_Pledge_19022009.zip target=NEW> For more details click here.</a>

Sterling Biotech Limited has informed the Exchange that the Company will publish Audited Results for the financial year ended December 31, 2008 instead of publishing unaudited quarterly results for the quarter ended on December 31, 2008.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 30166.97 lacs for quarter ending on 30-SEP-2008 against Rs. 24845.64 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 6124.98 lacs for the quarter ending on 30-SEP-2008 against Rs. 4983.23 lacs for the quarter ending on 30-SEP-2007.

Sterling Biotech Limited has informed the Exchange that the Board meeting held on July 31, 2008 the following decisions were taken: (1) Subject to approval of the members, the Board considered and approved the appointment of Shri Chetan J. Sandesara as Joint Managing Director of the Company w.e.f. July 15, 2008.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 27694.29 lacs for quarter ending on 30-JUN-2008 against Rs. 22706.31 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 5712.93 lacs for the quarter ending on 30-JUN-2008 against Rs. 4828.61 lacs for the quarter ending on 30-JUN-2007.

Sterling Biotech Limited has informed the Exchange that at the Meeting of Board of Directors of the company held on June 25, 2008, the Board has approved issue of secured Non Convertible Debentures(NCD) on private placement basis to the extent of Rs. 300 Crores on such terms and conditions as may be mutually agreed upon with the lenders/ subscribers of the NCDs in compliance with the Guidelines issued by SEBI and other regulatory requirements for issue of Debentures.